

TAXUS[®] Express^{2™}

Clinical Programs

Boston
Scientific

Clinical Trial
and Registry
Summary



WISDOM

International Registry

Objective:	Global transitional registry of TAXUS [®] Express ^{2™} Paclitaxel-Eluting Stent
Number of Patients:	778
Number of Sites:	22 sites in 9 countries
Lesion Type:	<i>de novo</i>
Stent Platform:	TAXUS Express ² and TAXUS Express [®] Paclitaxel-Eluting Stent
Release Kinetics:	Slow Release (SR)
Primary Endpoint:	1-Year site reported target lesion re-interventions
Principal Investigator:	Alexandre Abizaid, MD
Status:	Enrollment complete

*TAXUS Express² & Express
Paclitaxel-Eluting Stent*

Site Reported Cardiac Events	5.2% (37/717)	patient based
All Cause Death	2.2% (16/717)	patient based
Q-Wave MI	0.1% (1/717)	patient based
Non-Q-Wave MI	1.1% (8/717)	patient based
Target Lesion Re-Intervention	2.0% (17/832)	lesion based
TVR, Non-TLR	na	
TVR, TLR	na	
TVR, CABG	na	
Stent Thrombosis (< 365 days)	0.6% (4/717)	patient based

INDICATIONS

The TAXUS[®] Express[™] Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of *de novo* lesions ≤ 28 mm in length in native coronary arteries ≥ 2.5 to ≤ 3.75 mm in diameter.

CONTRAINDICATIONS

Use of the TAXUS Express² Paclitaxel-Eluting Coronary Stent System is contraindicated in patients with:

- Known hypersensitivity to paclitaxel or structurally related compounds.
- Known hypersensitivity to the polymer or its individual components.

Coronary Artery Stenting is contraindicated for use in:

- Patients in whom antiplatelet and/or anticoagulant therapy is contraindicated.
- Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or delivery device.

WARNINGS

- To maintain sterility, the inner package should not be opened or damaged prior to use.
- The use of this product carries the risks associated with coronary artery stenting, including subacute thrombosis, vascular complications, and/or bleeding events.
- Patients with known hypersensitivity to 316L stainless steel may suffer an allergic reaction to this implant.

Potential adverse events (in alphabetical order) which may be associated with the use of a coronary stent in native coronary arteries include but are not limited to:

Aneurysm, Arrhythmias, Bleeding complications, Death, Distal Emboli, Emergent CABG, Myocardial Infarction, Myocardial Ischemia, Occlusion, Stent Delivery Failures, Target Lesion Revascularization, Thrombosis, Vascular complications, Vessel Dissection.

Potential adverse events not captured above that may be unique to the paclitaxel drug coating:

Alopecia, Allergic reaction to the drug or the polymer, Anemia, Blood product transfusion, Gastrointestinal symptoms, Hematologic dyscrasia, Hepatic enzyme changes, Histologic changes in vessel wall, including inflammation, cellular damage or necrosis, Myalgia/Arthralgia, Peripheral neuropathy.

The safety and effectiveness of the TAXUS Express² Paclitaxel-Eluting Coronary Stent System have not been established in the following patient populations:

- Women who are pregnant or lactating.
- Men intending to father children.
- Pediatric patients.
- Patients with unresolved vessel thrombus at the lesion site.
- Patients with coronary artery reference vessel diameters < 2.5 mm or > 3.75 mm.
- Patients with lesions located in the saphenous vein grafts, in the unprotected left main coronary artery, ostial lesions, or lesions located at a bifurcation.
- Patients with diffuse disease or poor flow distal to the identified lesions.
- Patients with tortuous vessels (> 60 degrees) in the region of the obstruction or proximal to the lesion.
- Patients with a recent acute myocardial infarction where there is evidence of thrombus or poor flow.
- Patients with multiple overlapping stents.
- Patients with longer than 1-Year follow-up.

Prior to use, please see the complete "Directions for Use" at www.taxus-stent.com for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events and Operator's Instructions.

CAUTION

Federal law restricts this product to sale by or on the order of a physician.

TRADEMARKS

Express, Express², and TAXUS are trademarks of Boston Scientific Corporation or its affiliates.

**Boston
Scientific**

Delivering what's next.™

Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537
www.bostonscientific.com
www.taxus-stent.com

*To order product or for
more information, contact
customer service at
1.888.272.1001*

© 2006 Boston Scientific Corporation
or its affiliates. All rights reserved.
Express, Express², TAXUS and
Translute are trademarks of Boston
Scientific Corporation or its affiliates.
NIR is a registered trademark of
Medinol Ltd., Jerusalem, Israel.

USCV3111.114.7 03/06